iShares Biotechnology ETF
The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 1Y SHOWN · NET +$1.5B OVER THIS RANGE
Money keeps arriving — +$86M of net buying over the past month, about 0.8% of the fund's asset base, while the price has returned +28.4% so far this year. At 0.45% a year it is not the cheapest way in — IWM runs the same ground at 0.19%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS TODAY’S MOVE · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | AMGNAMGEN | 8.56% | $442.84 | +4.1% | ||
| 2 | VRTXVERTEX PHARMACEUTICALS | 7.92% | $548.42 | +3.7% | ||
| 3 | GILDGILEAD SCIENCES | 7.11% | $148.47 | +3.6% | ||
| 4 | REGNREGENERON PHARMACEUTICALS | 5.99% | $843.17 | +4.1% | ||
| 5 | MRNAMODERNA | 1.72% | $170.08 | +170.1% | ||
| 6 | ARGXARGENX SE | 3.78% | $1032.49 | +3.9% | ||
| 7 | NTRANATERA | 3.16% | $324.97 | +3.7% | ||
| 8 | RVMDREVOLUTION MEDICINES | 2.97% | $214.34 | -0.9% | ||
| 9 | BIIBBIOGEN | 2.25% | $221.01 | +4.0% | ||
| 10 | ALNYALNYLAM PHARMACEUTICALS | 2.20% | $242.69 | +6.1% | ||
| 11 | ILMNILLUMINA | 2.15% | $203.36 | +8.0% | ||
| 12 | ONCBeiGene | 2.13% | $378.08 | +2.4% | ||
| 13 | INSMINSMED | 2.03% | $128.99 | +0.3% | ||
| 14 | INCYINCYTE | 1.80% | $129.07 | +4.6% | ||
| 15 | UTHRUNITED THERAPEUTICS | 1.54% | $527.78 | +1.8% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.
Sign in to see all 221| 1 week | +8.1% |
| 1 month | +14.3% |
| 3 months | +32.3% |
| 6 months | +25.8% |
| YTD | +28.4% |
| 1 year | — |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | +$9M |
| 1 month | +$86M |
| 3 months | +$666M |
| YTD | +$130M |
| 1 year | +$1.5B |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 8.6% of the book; the top ten carry 46%. Spread across 234+ names, it behaves like roughly 32 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| MRNA MODERNA | $352M | $316M |
| TEM TEMPUS AI INC | $17M | $19M |
| AMGN AMGEN | $11M | $12M |
| ROIV ROIVANT SCIENCES | $1M | $16M |
| UTHR UNITED THERAPEUTICS | $15M | $1M |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat IBB on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| ITOT iShares Core S&P Total U.S. Stock Market ETF | 0.03% | $97.9B | +$245M | -42bp on fee · 10× the assets · +$245M in over the month | Head-to-head |
| IJH iShares Core S&P Mid-Cap ETF | 0.05% | $128.4B | +$547M | -40bp on fee · 13× the assets · +$547M in over the month | Head-to-head |
| IUSG iShares Core S&P U.S. Growth ETF | 0.04% | $33.8B | +$668M | -41bp on fee · 3× the assets · +$668M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $32.7B | +$104M | -41bp on fee · 3× the assets · +$104M in over the month | Head-to-head |
| IUSV iShares Core S&P U.S. Value ETF | 0.04% | $28.1B | +$103M | -41bp on fee · 3× the assets · +$103M in over the month | Head-to-head |